- Price
- $111.24
- Day
- -3.45%
- Mkt Cap
- $12.41B
- 52W Range
- $81.22 – $118.30
- Volume
- 2.26M
- Beta
- 1.07
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Revvity, Inc. (RVTY) Q2 2026 Earnings Call Transcript
Read full article
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today reported financial results for the second quarter ended July 5, 2026. The Company reported GAAP earnings per share from continuing operations of $0.48, as compared to $0.47 in the same period a year ago. Revenue for the quarter was $730 million, as compared to $720 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $89 million (which includes $16 million of tariff related.
Read full article
Revvity Inc (RVTY) released its 8-K filing detailing its earnings for the second quarter of 2026 on August 4, 2026. The company reported notable increases in re
Read full article
Medical equipment maker Revvity raised its annual profit and revenue forecasts on Tuesday, after topping Wall Street estimates for the second quarter helped by improving demand for its drug-development tools and diagnostic testing products.
Read full article
Revvity (RVTY) came out with quarterly earnings of $1.41 per share, beating the Zacks Consensus Estimate of $1.23 per share. This compares to earnings of $1.18 per share a year ago.
Read full article
Revvity beats Q2 earnings and sales estimates as Diagnostics growth, wider margins and strong cash flow support a higher 2026 outlook.
Read full article
WALTHAM, Mass.--(BUSINESS WIRE)--The Board of Directors of Revvity, Inc. (NYSE: RVTY), today declared a regular quarterly dividend of $0.07 per share of common stock. This dividend is payable on November 13, 2026 to all shareholders of record at the close of business on October 23, 2026. About Revvity At Revvity, “impossible” is inspiration, and “can't be done” is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows fr.
Read full article
Revvity, Inc. RVTY is slated to report second-quarter 2026 results on Aug. 4, before market open.
Read full article
Bank of Nova Scotia lifted its position in shares of Revvity Inc. (NYSE: RVTY) by 436.4% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 58,546 shares of the company's stock after buying an additional 47,631 shares during
Read full article
Revvity (RVTY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read full article
RVTY's T-SPOT A201 targets a 2027 launch, promising high-throughput latent TB testing with greater lab efficiency and scalability.
Read full article
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. today announced the development of the T-SPOT™ A201, a next-generation high-throughput automated platform designed to support the performance advantages of T-SPOT.TB™ testing for large-volume clinical labs, enabling a reliable, accurate solution for latent tuberculosis (TB) detection. Tuberculosis remains a critical global health challenge, with testing demand driven by immigration screening, pre-treatment evaluation for immunosuppressive therapies.
Read full article